WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY

Tanaka Y.; Aletaha D.; Peterson S.; Ganguly R.; Kurrasch R.; Popik S.; Agarwal P.; Li N.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY

【24h】

WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY

机译：在活性类风湿性关节炎患者中，使用抗IL-6细胞因子单克隆抗体的抗IL-6细胞因子单克隆抗体的工作生产力和一般健康状况改善，尽管抗TNF治疗，所以第3期Sirrow-T研究结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共1页
作者
Tanaka Y.; Aletaha D.; Peterson S.; Ganguly R.; Kurrasch R.; Popik S.; Agarwal P.; Li N.;
展开▼
作者单位

Univ Occupat &

Environm Hlth Kitakyushu Fukuoka Japan;

Med Univ Vienna Div Rheumatol Vienna Austria;

Janssen Res &

Dev LLC Spring House PA USA;

GlaxoSmithKline Collegeville PA USA;

GlaxoSmithKline Collegeville PA USA;

Janssen Res &

Dev LLC Spring House PA USA;

Janssen Res &

Dev LLC Spring House PA USA;

Janssen Res &

Dev LLC Spring House PA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY [J] . Tanaka Y., Aletaha D., Peterson S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：在活性类风湿性关节炎患者中，使用抗IL-6细胞因子单克隆抗体的抗IL-6细胞因子单克隆抗体的工作生产力和一般健康状况改善，尽管抗TNF治疗，所以第3期Sirrow-T研究结果
2. RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT (SIRROUND-D) [J] . Takeuchi T., Thorne C., Karpouzas G., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：患有活动性类风湿关节炎病情缓解（病情改变）的患者中西鲁单抗（一种抗IL-6细胞因子单克隆抗体）西鲁单抗的有效性和安全性的第3阶段，随机，双盲，局部对照研究的结果SIRROUND-D）
3. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study [J] . Aletaha Daniel, Bingham Clifton O. III, Tanaka Yoshiya, The Lancet . 2017,第10075期

机译：Sirukumab对抗TNF治疗难治性的患者Sirukumab的疗效和安全性（SiRROUD-T）：随机，双盲，安慰剂控制，并行组，跨国，第3期研究
4. Lack of response to classic treatment is associated with anti-cyclic citrullinated peptide antibodies but not with drb1-se status in patients with recent-onset rheumatoid arthritis [C] . Manzanares B., Martinez F., Gonzalez R., European Congress of Immunology . 2009

机译：缺乏对经典治疗的反应与抗循环瓜氨酸肽抗体有关，但近期发病类风湿性关节炎的患者没有使用DRB1-SE状态
5. A prevalence-based case-control study of the association between mental health and exposure to anti-TNFα biologic therapy: Evidence of a role for macrophage cross-linking by monoclonal antibodies in mental illness [D] . Burns, Craig Francis 2015

机译：基于流行的病例对照研究，研究心理健康与抗TNFα生物治疗的暴露之间的关联：单克隆抗体在精神疾病中巨噬细胞交联作用的证据
6. Extended report: Sirukumab a human anti-interleukin-6 monoclonal antibody: a randomised 2-part (proof-of-concept and dose-finding) phase II study in patients with active rheumatoid arthritis despite methotrexate therapy [O] . Josef S Smolen, Michael E Weinblatt, Shihong Sheng, -1

机译：扩展报告：Sirukumab人类抗白细胞介素6单克隆抗体：一项针对氨甲蝶呤治疗的活动性类风湿关节炎患者的随机2部分（概念验证和剂量确定）II期研究
7. FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study [O] . Y Tanaka, D Aletaha, S Peterson, 2017

机译：Fri0251 Sirukumab，一种抗IL-6细胞因子单克隆抗体，导致有效的类风湿性关节炎患者的工作生产率和一般健康状况，对抗TNF治疗的难治性：结果3 Sirround-T研究结果

WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY

著录项

相似文献

相关主题

期刊订阅